Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis?

Danninger, Kathrin; Hoppe, Uta C.; Pieringer, Herwig

doi:10.1111/1756-185x.12415

Cited by 35 publications

(29 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two trials, TRACE (Trial of Atorvastatin for Primary Prevention of Cardiovascular Events in RA), which was stopped early due to low event rate, and its predecessor, TARA (Trial of Atorvastatin in RA), showed statistically significant arthritis and lipid-control effects of statins [91, 92]. Another trial reported better articular response in RA patients receiving tofacitinib plus atorvastatin compared to tofacitinib monotherapy [93].…”

Section: Introductionmentioning

confidence: 99%

Managing Cardiovascular Disease Risk in Rheumatoid Arthritis: Clinical Updates and Three Strategic Approaches

Chodara

Wattiaux²,

Bartels³

2017

Curr Rheumatol Rep

View full text Add to dashboard Cite

The increase in cardiovascular disease (CVD) risk in rheumatoid arthritis (RA) is well known; however, appropriate management of this elevated risk in rheumatology clinics is less clear. Purpose of Review By critically reviewing literature published within the past five years, we aim to clarify current knowledge and gaps regarding CVD risk management in RA. Recent Findings We examine recent guidelines, recommendations, and evidence, and discuss three approaches: (1) RA-specific management including treat-to-target and medication management, (2) assessment of comprehensive individual risk, and (3) targeting traditional CVD risk factors (hypertension, smoking, hyperlipidemia, diabetes, obesity and physical inactivity) at a population level. Considering that 75% of US RA visits occur in specialty clinics, further research is needed regarding evidence-based strategies to manage and reduce CVD risk in RA. Summary This review highlights clinical updates including US cardiology and international professional society guidelines, successful evidence-based population approaches from primary care, and novel opportunities in rheumatology care to reduce CVD risk in RA.

show abstract

Section: Introductionmentioning

confidence: 99%

Managing Cardiovascular Disease Risk in Rheumatoid Arthritis: Clinical Updates and Three Strategic Approaches

Chodara

Wattiaux²,

Bartels³

2017

Curr Rheumatol Rep

View full text Add to dashboard Cite

show abstract

“…This persistent inflammatory response is also thought to be an underlying cause for the increased risk of developing CVD in patients with arthritis (1, 2). In this context, statins protect from CVD and recent studies suggest that they also reduce disease activity in patients with rheumatoid arthritis (4–11). It is evident that the pleiotropic actions of statins cannot be uniquely ascribed to inhibition of HMGCA reductase activity.…”

Section: Discussionmentioning

confidence: 99%

13‐Series resolvins mediate the leukocyte‐platelet actions of atorvastatin and pravastatin in inflammatory arthritis

et al. 2017

View full text Add to dashboard Cite

Rheumatoid arthritis is an inflammatory condition characterized by overzealous inflammation that leads to joint damage and is associated with an increased incidence of cardiovascular disease. Statins are frontline therapeutics for patients with cardiovascular disease and exert beneficial actions in rheumatoid arthritis. The mechanism that mediates the beneficial actions of statins in rheumatoid arthritis remains of interest. In the present study, we found that the administration of 2 clinically relevant statins—atorvastatin (0.2 mg/kg) or pravastatin (0.2 mg/kg)—to mice during inflammatory arthritis up-regulated systemic and tissue amounts of a novel family of proresolving mediators, termed 13-series resolvins (RvTs), and significantly reduced joint disease. Of note, administration of simvastatin (0.2 mg/kg) did not significantly up-regulate RvTs or reduce joint inflammation. We also found that atorvastatin and pravastatin each reduced systemic leukocyte activation, including platelet-monocyte aggregates (∼25–60%). These statins decreased neutrophil trafficking to the joint as well as joint monocyte and macrophage numbers. Atorvastatin and pravastatin produced significant reductions (∼30–50%) in expression of CD11b and major histocompatibility complex class II on both monocytes and monocyte-derived macrophages in joints. Administration of an inhibitor to cyclooxygenase-2, the initiating enzyme in the RvT pathway, reversed the protective actions of these statins on both joint and systemic inflammation. Together, these findings provide evidence for the role of RvTs in mediating the protective actions of atorvastatin and pravastatin in reducing local and vascular inflammation, and suggest that RvTs may be useful in measuring the anti-inflammatory actions of statins.—Walker, M. E., Souza, P. R., Colas, R. A., Dalli, J. 13-Series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis.

show abstract

“…In fact, a study suggested that a TZD antidiabetic agent pioglitazone, i.e., a synthetic ligand of PPAR, could improve both insulin resistance and the disease activity in RA . Furthermore, statins [or hydroxymethylglutaryl‐coenzyme A (HMG‐CoA) reductase inhibitors] can be used in RA to reduce serum lipid levels as well as improve the RA disease activity, owing to their anti‐inflammatory effects , . However, there have been no clear demonstrations of the direct modulatory role of ANGPTL4 or other PPAR‐modulating agents in the disease activity or the incidence of human RA; therefore, further studies are warranted.…”

Section: Angptl‐4mentioning

confidence: 99%

Angiopoietin-like 4: A molecular link between insulin resistance and rheumatoid arthritis

Masuko

2017

J. Orthop. Res.

View full text Add to dashboard Cite

Recent evidence suggests that common factor(s) or molecule(s) might regulate lipid and glucose metabolism, inflammation, and bone and cartilage degeneration. These findings may be particularly relevant for cases of rheumatoid arthritis, in which chronic inflammation occurs in an autoimmune context and causes the degradation of articular joints as well as insulin resistance and cardiovascular complications. Candidates for this common regulatory system include signals mediated by peroxisome proliferator-activated regulator and its response factor, angiopoietin-like 4. The expression and bioactivity of angiopoietin-like 4, an adipocytokine that was originally reported to have an angiogenic function, have been detected not only in the vascular system and adipose tissue but also in rheumatoid joints. An essential role for angiopoietin-like 4 has been established in dyslipidemia, and recent reports indicate that it may modulate bone and cartilage catabolism in rheumatoid arthritis. The enhanced expression of angiopoietin-like 4 in rheumatoid arthritis may explain the occurrence of insulin resistance, cardiovascular risk, and joint destruction, thereby suggesting that this molecule could be a potential target for anti-rheumatoid arthritis strategies. This review describes recent research on the role of angiopoietin-like 4 in chronic inflammatory conditions and rheumatoid arthritis, as well as potential therapeutic candidates. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 35:939-943, 2017.

show abstract

Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis?

Cited by 35 publications

References 19 publications

Managing Cardiovascular Disease Risk in Rheumatoid Arthritis: Clinical Updates and Three Strategic Approaches

Managing Cardiovascular Disease Risk in Rheumatoid Arthritis: Clinical Updates and Three Strategic Approaches

13‐Series resolvins mediate the leukocyte‐platelet actions of atorvastatin and pravastatin in inflammatory arthritis

Angiopoietin-like 4: A molecular link between insulin resistance and rheumatoid arthritis

Contact Info

Product

Resources

About